source
- OrbiMed secures $3 billion for new life science funds, with over $1 billion earmarked for AsiaOrbiMed, a leading global investor in life science companies, announced the closing of two new funds that together total about $3 billion. The capital will be deployed across a range of private equ…
- Vanda pauses social anxiety program after Phase 3 trial misses endpoint in womenVanda Pharmaceuticals announced Wednesday that it is halting development of its social anxiety disorder candidate after a late-stage trial did not achieve its primary goal. The experimental drug,…